

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) A method of monitoring and prognosticating the clinical outcome of an immunotherapy in a subject suffering from Alzheimer's disease and being immunized against a β -amyloid component, comprising the steps of:
 - (a) obtaining a test sample from the subject,
 - (b) contacting said test sample with a brain tissue section containing β -amyloid plaque,
 - (c) determining the level of immunoreactivity of said test sample with β -amyloid plaques present in said amyloid plaque-containing tissue section, and
 - (d) comparing said level of immunoreactivity to ~~(i) a reference level of immunoreactivity representing Alzheimer's disease, or (ii)~~ a level of immunoreactivity determined prior to onset of said immunotherapy in said subject, wherein ~~a higher level of immunoreactivity as compared to the reference level of immunoreactivity or an increase in the level of immunoreactivity as compare to the level of immunoreactivity determined prior to onset of said immunotherapy in said subject, is indicative of a positive clinical outcome of said immunotherapy.~~
2. - 3. (canceled)
4. (previously presented) The method according to claim 1, wherein said test sample is a body fluid.
5. (currently amended) The method according to claim 1, wherein said brain tissue section amyloid plaque-containing sample is

obtained from a transgenic non-human animal.

6. (currently amended) The method according to claim 1, wherein said amyloid plaque-containing sample is a tissue section from a transgenic non-human animal.
7. (currently amended) The method according to claim 1, wherein said ~~amyloid plaque containing sample is a~~ brain tissue section is from a non-human animal transgenic for human amyloid precursor protein (APP), or a fragment, or a derivative, or a mutant thereof, and wherein the expression of said transgene results in said non-human animal exhibiting a predisposition to developing amyloid plaques.
8. - 10 (canceled)
11. (withdrawn) A kit for monitoring an immunotherapy in a subject suffering from a neurodegenerative disease associated with the deposition of abnormal protein aggregates, said kit comprising a solid phase containing on its surface an abnormal protein aggregate-containing sample.
12. (withdrawn) The kit according to claim 11, wherein said abnormal protein aggregate-containing sample is obtained from a transgenic non-human animal.
13. (withdrawn) The kit according to claim 11, wherein said abnormal protein aggregate-containing sample is a tissue section from a transgenic non-human animal.
14. (withdrawn) The kit according to claim 11, wherein said abnormal protein aggregate-containing sample is a tissue section from a non-human animal transgenic for a human protein, or a fragment, or a derivative, or a mutant thereof, wherein said human protein is a component of said abnormal protein aggregate, and wherein

Applicants: Cristoph Hock et al.
Serial No.: 10/554,314
Filed: April 19, 2006
Page 4

the expression of said transgene results in said non-human animal exhibiting a predisposition to developing abnormal protein aggregates.

15. (withdrawn) The kit according to claim 14, wherein said human protein is the amyloid precursor protein (APP), or a fragment, or a derivative, or a mutant thereof.
16. (withdrawn) The kit according to claim 11, wherein said neurodegenerative disease is an amyloidogenic disease.
17. (withdrawn) The kit according to claim 16, wherein said amyloidogenic disease is Alzheimer's disease.
18. (previously presented) The method according to claim 4, wherein said test sample is serum or cerebrospinal fluid.